Market Place
Sourcing Support
Novartis Scemblix ph III data first to show superior efficacy tolerability
03 Jun 2024 //
PHARMABIZ
FDA approves decade-old Pfizer drug for rare childhood leukemia
28 Sep 2023 //
ENDPTS
Amber Specialty Added to Pfizer’s Limited Distribution Network
03 Aug 2022 //
BUSINESSWIRE
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR
08 Dec 2020 //
PRNEWSWIRE
Novartis’ phase III ASCEMBL study of asciminib vs bosutinib meets primary
26 Aug 2020 //
PHARMABIZ
List of Paragraph IV Patent Certifications (PPIV) as of December 3, 2018
12 Dec 2018 //
FDA
Biogen, Ionis collaborate to identify therapies to treat spinal muscular atrophy
20 Dec 2017 //
PHARMABIZ
Avillion Announces US Approval of Pfizer`s BOSULIF® (bosutinib)
19 Dec 2017 //
PR NEWSWIRE
Pfizer, Avillion file for Bosulif expansion
31 Aug 2017 //
PHARMA TIMES
U.S. FDA & EMA Accept Regulatory Submissions for BOSULIF® (bosutinib)
29 Aug 2017 //
BUSINESSWIRE
NICE backs routine use of Incyte’s leukaemia drug
14 Feb 2017 //
PHARMATIMES
Pfizer Reports Positive Top-Line Results For Phase 3 BFORE Study Of BOSULIF
06 Dec 2016 //
NASDAQ
NICE expands NHS treatment options for CML, lung cancer
25 Aug 2016 //
PHARMATIMES
BCR-ABL Tyrosine Kinase Inhibitors - Risk of Hepatitis B Reactivation
06 May 2016 //
HEALTH CANADA
Health Canada Require Updated Warning on Gleevec Labeling for Brand and Generics
05 May 2016 //
TWOFOUR INSIGHT
BCR-ABL Tyrosine Kinase Inhibitors
04 May 2016 //
HEALTH CANADA
Twenty-three therapies axed from Cancer Drugs Fund
08 Sep 2015 //
PHARMATIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.